MedTrace Logo

Glutaminergic Agents for Cocaine Abuse - 5

NCT00000280 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2017-04-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate glutaminergic agents for cocaine abuse.

Conditions

  • Cocaine-Related Disorders

Interventions

DRUG

Nimodipine

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • VA Connecticut Healthcare System

    collaborator FED

  • Yale University

    lead OTHER

Principal Investigators

  • Thomas R Kosten, M.D. · VA Connecticut Healthcare System

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-09-30
Primary Completion
1999-08-31
Completion
1999-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000280 on ClinicalTrials.gov